- Home
- Companies
- Dyadic International, Inc.
- Products
- Dapibus - Filamentous Fungal Protein ...
Dapibus - Filamentous Fungal Protein Platform for Food Production
Dyadic’s newly developed Dapibus™ filamentous fungal based microbial protein production platform is reenginnered to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness. The current focus for the Dapibus™ platform is in our Alternative Proteins business segment. Given the Dyadic’s industrial heritage, the expertise to rapidly achieve commercial scale within margin sensitive markets such as food and nutrition enzymes, provides our partners with the ability to move from demonstration to commercial production quickly and efficiently.
- Current projects in cell culture media, enzymes, and growth factors to enable commercial scale production or reduce costs in both plant and lab-grown meat segments.
- Internal projects directed at lowering the costs of research and product development through production of high-quality and affordable recombinant proteins and enzymes at different grades.
Meeting the growing demand for proteins worldwide for human and animal health with highly productive scalable microbial biomanufacturing platforms and products.
To improve how we feed, fuel, and heal the world by utilizing modern biotechnology to revolutionize medicine, agriculture, nutrition, and food.
Current ChallengesCurrent methods to produce high quality and high throughput proteins at low cost are not adequate to meet the growing global demand for vaccines, monoclonal and other antibodies, therapeutic proteins, as well as food, nutrition, and diagnostic enzymes and proteins.
The pandemic has highlighted key challenges that have existed within biomanufacturing that will only increase as demand or circumstances, such as a global pandemic or endemic threat, climate change, and population increase continue to drive rising demand not only for lifesaving biologic products but also food and nutrition products.
Shortened timeframes and shortage of raw materials, equipment, consumables, lipid nanoparticles due to high demand
Examples: Cell culture media, Bioreactor bags, vials, tangential flow filters
Inherent challenges include time to produce new cell lines, drug substance, process optimization, aseptic techniques, cold manufacturing
Infrastructure and production requirements, cold storage and distribution challenges, geographic challenges
- Stable Cell lines in ~7 weeks
- Research Cell Bank becomes Master Cell Bank
- No viral or endotoxin inactivation
- 3-7 day fermentation (continuous in development)
- Up to 300 times more productive than certain currently used vaccine cell lines
- Up to 10 times more productive than certain currently used mammalian cell lines
- Industrially proven platform that has run at up to 500,000L
- Record levels of 10g/L of an antigen, >22 g/L of a monoclonal antibody
- Industrial scale flexibility and scale
- C1 can lower CAPEX:
- Produce at smaller scale while dramatically increasing protein yields
- Unparallelled productivity provides margin relief
- C1 can lower OPEX
- Smaller facility footprint and related costs
- Industrial media costs for pharma grade materials